2025-04-13 - Analysis Report
## Johnson & Johnson (JNJ) Stock Review

**0. Executive Summary:**

Johnson & Johnson (JNJ), a leading healthcare company, shows a cumulative return significantly lagging behind the S&P 500 (VOO) over the analyzed period. While exhibiting relatively stable profitability, recent performance indicates underperformance compared to the market benchmark, warranting further investigation into its potential for future growth.


**1. Performance Comparison:**

Johnson & Johnson (JNJ) is a multinational corporation that manufactures and sells medical devices, pharmaceuticals, and consumer packaged goods.

* **JNJ Cumulative Return:** 24.31%
* **VOO (S&P 500) Cumulative Return:** 66.36%
* **Return Difference:** -42.04%  (JNJ underperformed VOO by 42.04%)
* **Relative Divergence:** 36.6% (Indicates JNJ's performance is relatively lower compared to its historical performance range against VOO).

The provided alpha and beta analysis reveals mixed results across different periods.  While some periods show positive alpha (outperformance relative to the market), recent years (2021-2025) show negative or very low CAGR and negative alpha, suggesting underperformance against the market.  The beta consistently remains around 0.0-0.7, implying low market sensitivity.


| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 28.0% | 56.0% | -1.0% | 0.0 | 275.3 |
| 2016-2018  | 10.0% | 10.8% | -7.0% | 0.0 | 261.2 |
| 2017-2019  | 20.0% | 10.8% | -9.0% | 0.7 | 303.6 |
| 2018-2020  | 14.0% | 59.8% | -12.0% | 0.5 | 336.4 |
| 2019-2021  | 28.0% | 59.9% | -26.0% | 0.3 | 374.9 |
| 2020-2022  | 4.0% | 61.2% | -2.0% | 0.3 | 397.3 |
| 2021-2023  | -19.0% | 61.2% | -35.0% | 0.4 | 363.2 |
| 2022-2024  | -31.0% | 61.2% | -47.0% | 0.3 | 345.7 |
| 2023-2025  | -2.0% | 69.6% | -16.0% | 0.2 | 365.6 |


**2. Recent Price Movement:**

* **Closing Price:** $151.73
* **5-Day Moving Average:** $150.40
* **20-Day Moving Average:** $158.46
* **60-Day Moving Average:** $157.33

The price is currently below both the 20-day and 60-day moving averages, suggesting a potential downward trend.  The recent price change of +2.04 from the previous close indicates a minor positive bounce.


**3. Technical Indicators:**

* **Market Risk Indicator (MRI):** 0.47 (High Risk)
* **RSI:** 36.36 (Approaching oversold territory)
* **PPO:** -0.84 (Negative, suggesting bearish momentum)
* **20-Day Relative Divergence Change:** -11.0% (Short-term downtrend)
* **Expected Return:** -48.2% (Significant negative expected return relative to the S&P 500 over the long term.)

The combination of a high MRI, low RSI, negative PPO, and negative relative divergence suggests a bearish outlook.  The recent price increase should be viewed cautiously within this context.  The -48.2% expected return relative to S&P 500 over the long term highlights significant underperformance concerns.


**4. Recent Earnings Analysis:**

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2024-10-23 | $1.12 | $22.47B      |
| 2024-07-25 | $1.95 | $22.45B      |
| 2024-05-01 | $1.35 | $21.38B      |
| 2024-02-16 | $1.68 | $21.39B      |
| 2023-10-27 | $10.32| $21.35B      |

EPS shows significant volatility, with a large spike in October 2023. This requires further investigation to understand the underlying causes. Revenue remains relatively stable.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue  | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $22.52B | 68.35%       |
| 2024-09-30 | $22.47B | 69.01%       |
| 2024-06-30 | $22.45B | 69.40%       |
| 2024-03-31 | $21.38B | 69.55%       |
| 2023-12-31 | $21.39B | 68.23%       |

Revenue shows stability, with profit margins remaining consistently high (above 68%).

**Capital and Profitability:**

| Quarter | Equity   | ROE    |
|---------|----------|--------|
| 2024-12-31 | $71.49B | 4.80%  |
| 2024-09-30 | $70.16B | 3.84%  |
| 2024-06-30 | $71.54B | 6.55%  |
| 2024-03-31 | $70.02B | 4.65%  |
| 2023-12-31 | $68.77B | 5.89%  |

Equity fluctuates, and ROE shows some variation.  Further analysis is needed to understand the drivers behind these fluctuations.


**6. Overall Analysis:**

JNJ's recent performance lags significantly behind the S&P 500. While the company demonstrates consistent profitability and revenue stability, the negative alpha, negative expected return, bearish technical indicators (high MRI, low RSI, negative PPO), and the recent significant drop in EPS raise serious concerns about future performance.  The large difference between the cumulative returns of JNJ and VOO (42.04%)  combined with the negative expected return clearly signals underperformance.  A deeper dive into the reasons behind the EPS volatility and the negative long-term expected return is crucial before making any investment decisions.  The current indicators suggest a cautious outlook.
